Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 3, 2002, Pages 345-350

  Jung, Saera ^a   Lee, Han Chu ^a   Han, Ji Min ^a   Lee, Yun Jung ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Kwon, Youngmee ^a   Yu, Eunsil ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Fibrosing cholestatic hepatitis; Hepatitis B virus; Immunosuppression; Lamivudine

Indexed keywords

LAMIVUDINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTROLLED STUDY; DEATH; FIBROSING CHOLESTATIC HEPATITIS; FOLLOW UP; GRAFT SURVIVAL; HEALTH STATUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; KIDNEY GRAFT; LIVER FAILURE; LIVER FUNCTION; MALE; PRIORITY JOURNAL; SEPSIS;

EID: 0036091805     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02600.x     Document Type: Article

References (25)

1. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
2. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation
3. Fibrosing cholestatic hepatitis in renal transplant recipients
4. Hepatitis-B-virus-related fibrosing cholestatic hepatitis after renal transplantation with acute graft failure following interferon-α therapy
5. Fibrosing cholestatic hepatitis after living related-donor renal transplantation
6. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation
7. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B
8. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment
9. Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant
10. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy
11. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine
12. Treatment of fibrosing cholestatic hepatitis with lamivudine
13. Nucleoside analogue therapy in fibrosing cholestatic hepatitis - A case report in an HBsAg positive renal transplant recipient
14. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir
15. A one-year trial of lamivudine for chronic hepatitis B
16. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma
17. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
18. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma
19. Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture
20. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation
21. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation
22. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
23. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
24. Nucleoside analogues in the treatment of chronic hepatitis B
25. Clinical potential of emerging new agents in hepatitis B